Abstract
Twenty-seven postmenopausal women with advanced breast cancer were treated with the potent LHRH-agonist buserelin. The drug was given s.c. three times daily at a daily dosage of 3 mg the first week and subsequently of 2 mg daily. Although pituitary gonadotropins were suppressed in all cases, no response was observed in 26 evaluable patients. This study does not confirm earlier findings suggesting a role for LHRH-agonists in the treatment of postmenopausal patients with breast cancer.
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Adrenal Cortex Hormones / blood
-
Adult
-
Aged
-
Breast Neoplasms / blood
-
Breast Neoplasms / drug therapy*
-
Buserelin / therapeutic use*
-
Estradiol / blood
-
Female
-
Follicle Stimulating Hormone / blood
-
Humans
-
Injections, Subcutaneous
-
Luteinizing Hormone / blood
-
Menopause
-
Middle Aged
-
Prolactin / blood
-
Testosterone / blood
-
Thyroid Hormones / blood
Substances
-
Adrenal Cortex Hormones
-
Thyroid Hormones
-
Testosterone
-
Estradiol
-
Prolactin
-
Luteinizing Hormone
-
Follicle Stimulating Hormone
-
Buserelin